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Background: Mucopolysaccharidosis IVA (MPS IVA), or Morquio Syndrome type A, is an autosomal recessive
disease caused by deﬁciency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS), resulting
in excessive lysosomal storage of keratan sulfate in many tissues and organs. This accumulation causes a
severe skeletal dysplasia with short stature, and affects the eye, heart and other organs, with many signs and
symptoms. Morquio A syndrome is estimated to occur in 1 in 200,000 to 300,000 live births. Clinical trials with
enzyme replacement therapy for this disease are in progress, and it is probable that the treatment, when
available, would be more effective if started early. We describe an innovative ﬂuorometric method for the
assay of GALNS in dried blood spots (DBS).
Methods: We used dried blood spots (DBS) as the enzyme source and compared it with leukocytes samples,
having studied 25 MPS IVA patients and 54 healthy controls. We optimized the assay conditions, including
incubation time and stability of DBS samples. To eppendorf type tubes containing a 3-mmdiameter blood spot
we added elution liquid and substrate solution. After 2 different incubations at 37 °C, the amount of
hydrolyzed product was compared with a calibrator to allow the quantiﬁcation of the enzyme activity. Results
in DBS were compared to the ones obtained in leukocytes using the standard technique.
Results: The ﬂuorescent methodology was validated in our laboratory and the assay was found sensitive and
speciﬁc, allowing reliable detection of MPS IVA patients. The use of DBS simpliﬁes the collection and transport
steps, and is especially useful for testing patients from more remote areas of large countries, and when
samples need to cross country borders.
Conclusion: This assay could be easily incorporated into the protocol of reference laboratories and play a role
in the screening for MPS IVA, contributing to earlier detection of affected patients.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Morquio disease type A or mucopolysaccharidosis IVA (MPS IVA)
is an autosomal recessive disorder caused by an intralysosomal defect
which affects the degradation of keratan sulfate [1,2]. This glycos-
aminoglycan is formed by N-acetylglucosamine (or acetylgalactosa-
mine) and galactose, and is an essential component of cartilage and
cornea.
At least 2 enzymes contribute to the degradation of keratan
sulfate: galactose-6-sulfate sulfatase (GALNS, which is deﬁcient in, Hospital de Clinicas de Porto
egre – RS, Brazil. Tel.: +55 51
i).
vier OA license.MPS IVA) and β-galactosidase (which is deﬁcient in MPS IVB) [1–4].
Although the short stature and progressive skeletal dysplasia are
usually more marked on MPS IVA, it is not possible to differentiate
MPS IVA from MPS IVB just by clinical data, these disorders being
examples of diseases in which the same phenotype is caused by
different enzyme defects [4,5].
MPS IVA is clinically characterized by multisystem involvement,
affecting mainly the skeletal, cardiopulmonary and visual systems,
with short stature, corneal clouding, dysostosis multiplex, joint
contractures and tooth enamel defect, among other signs and
symptoms. The cognitive and mental developments are normal. The
symptoms usually become apparent by the end of the ﬁrst or second
years of life, with a progressive decrease of growth velocity. The
patient usually reaches a ﬁnal stature between 113 and 122 cm,
presenting kyphosis, pectus carinatum, kyphoscoliosis and character-
istic facies [2–9].
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1806 M.V. Camelier et al. / Clinica Chimica Acta 412 (2011) 1805–1808The initial investigation of MPS can be done by the analysis of
urinary GAGs, including the measurement of total GAGs, which is
increased in almost all MPS patients, and the identiﬁcation of the
types of GAGs excreted (usually by electrophoresis or thin-layer
chromatography). These preliminary investigations help to focus the
investigation to a few speciﬁc types. In the case of MPS IVA, the
unusual GAG component which is mainly increased is keratan-sulfate.
The deﬁnitive diagnosis of MPS IVA is then established by the
measurement of GALNS activity using leukocytes or cultured
ﬁbroblasts, usually by a ﬂuorimetric method [10].
The need of whole blood samples to extract leukocytes, although
more convenient than collecting a skin biopsy to obtain ﬁbroblasts,
demands that the sample reacts in the laboratory in a relatively short
time after the collection (Burin et al. 2000) [11].This complicates the
use of leukocytes in large countries, in regions with deﬁcient transport
systems, and especially when samples have to cross international
borders, due to customs and sanitary restrictions.
The use of dried blood samples (DBS) collected on ﬁlter paper
could be an alternative as a screening method, and is already being
used for the detection of several lysosomal diseases, including MPS I,
II, IIIB, IVB, VI and VII (Chamoles et al.[12]; Civallero et al.[13]).
Although the use of DBS facilitates sample collection and transporta-
tions, especially when large distances are involved and/or borders
should be crossed, the conﬁrmation of an abnormal result in
leukocytes or ﬁbroblasts is still recommended. The fact that a speciﬁc
treatment for MPS IVA is in clinical development – a protocol with
intravenous enzyme replacement therapy is already in phase III
(www.bmrn.com) – makes it more important to have available,
simple and easy technique for the detection of the enzyme deﬁciency
in a convenient sample.
2. Material and methods
All participants/guardians signed informed consent forms approved
by the Institutional Review Board. Leukocytes and dried blood samples
(DBS) were obtained from 54 healthy individuals (18–50 y) and from 25
patients (3–47 y)withmucopolysaccharidosis type IVAwhose diagnosis
was previously conﬁrmed in leukocytes through the method described
by Van Diggelen et al. [10]. The DBS samples were prepared using
Whatman paper # 903, according to the requirements of the National
Committee for Clinical Laboratory Standards protocol (NCCLS).[14], and
were stored at 4 °C until the analyses were performed.
Leukocytes were separated from heparinized blood according to
the method described by Skoog et al. [15], and stored at−20°C until
the analysis. The leukocyte samples were diluted in distilled water
and were soniﬁed in Ultrasonic Sonicator Processor MISONIX label.
The Lowry method was used for the measuring proteins in leukocyte
samples [16]. To validate the method, we carried out a simultaneous
GALNS assay in leukocytes and DBS. For GALNS measurement in
leukocytes, we used the method described by Van Diggelen et al. [10]
and by Tylki-Szymanska et al. [17], with 4-methylumbelliferyl-β-D-
galactoside-6-sulphate (MU-βGal-6S, Moscerdam, Rotherdam) as
substrate. The 20 μl leukocyte homogenate (10 μg protein) was
incubated at 37 °C with the substrate and dilution buffer for 17 h in
the ﬁrst incubation and for 2 h in the second incubation, when
exogenous β-galactosidase galactohydrolase was added (Table 1). For
blanks, bovine serum albumin (BSA) 0.2% was used instead of sample.
After the whole reaction, ﬂuorescence (excitation, 365 nm; emission
450 nm) was measured on a Hitachi spectroﬂuorometer, model
F2000. Readings were corrected for blanks, and compared with 4-
methylumbelliferone calibrators. Enzyme activity was calculated as
nanomoles of substrate hydrolyzed per 17 h/mg of protein. For the
assay on DBS, we adapted the same method described by Van
Diggelen et al. and by Tylki-Szymanska et al. [10,17]. DBS were
collected and dryed following standard procedures. A single 3.0-mm
diameter disk containing dried blood samples (~3.6 μl whole blood)
Table 2
N-acetyl-galactosamine-6-sulfatase and β-galactosidase (reference enzyme) activities
on different samples.
Method n Activities range⁎ (mean±SD) p Cut-off value
N-acetylgalactosamine-6-sulfatase
Leukocytesa
MPS IV-A patients 25 0.0–6.0 (1.03±1.63) b0.001 37
Normal controls 54 68–352 (192.7±73.10)
DBSb
MPS IVA patients 25 0–1.25 (0.10±0.33). b0.001 3.5
Normal controls 54 5.75–33.45 (13.64±5.98).
β-galactosidase
DBSc
MPS IVA patients 25 20–57 (36.25±11.95).
Normal controls 54 20–66 (42.04±11.27).
⁎Activities expressed as: (a) nmol/17 h/mg protein; (b) nmol/48 h/ml : (c) nmol/h/ml.
1807M.V. Camelier et al. / Clinica Chimica Acta 412 (2011) 1805–1808was incubated at 37 °C for 48 h with appropriate artiﬁcial substrates
and dilution buffer in the ﬁrst incubation, and for 6 h in the second
incubation, as already described above for leukocytes (details in
Table 1). Stopping buffer was added to the blanks before substrate.
After incubation, the samples were centrifuged at 1500×g for 10 min
at room temperature. Fluorescence (excitation, 365 nm; emission,
450 nm) was measured in the supernatant on a Hitachi spectroﬂu-
orometer, model F2000. Readings were performed using the same
parameters as for leukocytes assay, and the enzyme activity was
calculated as nanomoles of substrate hydrolyzed per 48 h/ml of blood
(3.6 μl of blood per punch of DBS sample is assumed).
The stability of DBS was evaluated in several storage conditions
(temperature and days of storage), in samples collected from 2
patients and 3 controls. After drying overnight at room temperature
(22 °C), the measured activity of GALNS was performed and
considered 100%. Additional spots of the same sample were assayed
after storage at 4 °C, 22 °C and 37 °C for 7, 14 and 30 days.
The intra-assay CVs of GALNS in DBS was calculated by the
duplicate measurement of the enzyme in all patients (n=25) and
controls (n=54). The inter-assay variation coefﬁcient was calculated
by measurement of the enzyme activity of 3 control DBS samples in
three different assays carried out on the same day (all tests performed
in duplicate). The non-parametric Mann–Whitney U test was used to
measure the differences between controls and patients. A pb0.05 was
considered to be signiﬁcant. Receiver operating characteristic (ROC)
curves were used to calculate speciﬁc cut-off values for adult controls
and patients (Table 2). The Bonferroni test for multiple comparisons
was used to measure the differences for the stability study. AllFig. 1. Activity of GALNS in patient' and canalyses were performed using the Statistical Program Social Sciences
(Chicago, IL).
3. Results and discussion
The main adaptation of the leukocytes method described by van
Diggelenet al. [10] for the assayonDBSwas the increaseof the incubation
times: 31 hmore for the ﬁrst incubation (total of 48 h) and 4 hmore for
the second incubation (total of 6 h). Table 2 shows GALNS activity in
leukocytes and in DBS samples. In all patients with MPS IVA we could
detect the enzyme deﬁciency in leukocytes and in DBS samples. A
statistically signiﬁcant difference was observed in GALNS activity
between control and MPS IVA patient groups in both samples (Fig. 1).
The intra-assay CVs of controls (n=54) and patients (n=25) in
DBS samples was ≤12%. The inter-assay variation coefﬁcient on the
DBS samples analyses in 3 different assays was ≤13%. The stability
tests showed that, when the sample was kept at 4 °C, the activity was
between 97 and 100% of initial activity up to 30 days after collection.
When maintained at room temperature (22 °C), we observed an
activity of 80% at day 7 (not statistically different if compared to
reference value), 38% at day 14 and 2% at day 30 (both statistically
different if compared to reference value). The samples stored at 37 °C
for 7, 14 and 30 days had an activity of 10%, 2% and 0%, respectively,
close to the results obtained in fresh patient samples (Fig. 2).
We observed a signiﬁcant increase on the readings of blanks in the
samples stored at 22 °C (at 14 and 30 days), and in the samples stored
at 37 °C (at 7, 14 and 30 days). The Bonferroni test for the time stability
evaluation showed variations from time 0 to 14 days and from 0 to
30 days (p=0.004), with other variations related to storage time being
not signiﬁcant. Regarding temperature, a statistically signiﬁcant
difference was observed with all temperatures (pb0.005). In the
patients' samples, no effects of storage temperature and length of
storage were observed as the activity was close to zero in all conditions.
These results indicate that DBS samples collected for the
measurement of GALNS activity should be kept at 4 °C whenever
possible, being stable at this temperature for at least 30 days.
Shipment on ice packs seems to be not strictly necessary provided
the sample arrives at the laboratory before 7 days after collection. In
areas where high temperatures may occur, shipment in insulated
packs, preferably with ice, should be considered. Another useful
recommendation would be the simultaneous shipment of negative
control samples. The information about collection date of the sample
is critical and should be included.
A precaution should be taken for the measurement of enzyme
activity, related to the blood concentration in ﬁlter paper, which is not
always constant. This concentration depends mainly on the sample'sontrols' leucocytes and DBS samples.
Fig. 2. Effects of temperature and length of storage on the activity of GALNS in DBS.
1808 M.V. Camelier et al. / Clinica Chimica Acta 412 (2011) 1805–1808collection procedures [13]. To minimize this variation it is recom-
mended that a reference enzyme is measured in each sample, and we
generally use β-galactosidase for this purpose (Table 2) [13].
However, when a deﬁcient activity of GALNS is found, the assay of
another sulphatase would be advisable to rule out the possibility of
multiple sulphatase deﬁciency.
A positive correlation occurs between the leukocyte count in blood
and the degree of enzyme activity measured in DBS samples.[12].The
decrease in enzyme activity related to a low leukocyte count could be
easily identiﬁed by the simultaneous assay of several enzymes, with
the observation of their ratios [12].
A DBS method was already proposed for the diagnosis of MPS IVA
by Hopwood et al. [18], based in an indirect immunoquantiﬁcation.
Due to limited antibody availability, however, this method is not
accessible for most diagnostic laboratories. Also, a DBS method was
proposed by Khaliq et al. [19], based on tandem mass spectrometry,
but this technology is largely unavailable in most clinical laboratories.
In our hands, this method of GALNS in DBS samples allowed a
practical and reliable enzyme test for the identiﬁcation of MPS IVA
patients. This work shows that DBS samples can be used for the
detection of MPS IVA, with a method which could be easily
incorporated into the protocol of reference laboratories, enabling
easier identiﬁcation of affected patients, especially in areas with
difﬁculties for collection and transportation of liquid samples. This is
especially important as the enzyme replacement therapy is being
developed for MPS IVA, making speciﬁc and timely diagnosis of
affected patients critical for introduction of appropriate therapy and
for a better treatment outcome.
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